Armis Biopharma, Inc. is an established, late-stage clinical biopharmaceutical company having developed a pipeline of targeted anti-infective therapeutics designed to address the serious and rapidly growing phenomenon of antibiotic resistance and healthcare-associated infection. A primary area of focus in the firm are efficacious, non-systemic, non-resistant antimicrobials that work as monotherapies and/or may increase the efficacy of existing systemic antibiotics.
